BiotechTube
Home/Pipeline/Early I-O Pipeline

Early I-O Pipeline

Various Solid Tumors

Pre-clinical / Phase 1Active early development

Key Facts

Indication
Various Solid Tumors
Phase
Pre-clinical / Phase 1
Status
Active early development
Company
Ipsen

About Ipsen

Ipsen is a global specialty-care biopharmaceutical company with a focused mission to develop and commercialize innovative medicines in oncology, rare diseases, and neuroscience. Under CEO David Loew, the company has achieved strong commercial execution, delivering over 9% sales growth in 2024 and upgrading guidance in 2025, underpinned by a robust balance sheet and investment-grade credit ratings. Its strategy centers on deep therapeutic area specialization, a balanced internal and external innovation model, and leveraging its unique toxin platform to build a sustainable, high-growth pipeline.

View full company profile

Therapeutic Areas

OncologyRare DiseasesNeuroscience

Other Various Solid Tumors Drugs

DrugCompanyPhase
NUC-8232NuCanaPhase 1
TCR Library ProgramMedigeneDiscovery
Guardant Infinity Biomarker DiscoveryGuardant HealthDevelopment/Commercial
Cytotoxic Oncology GenericMSN LaboratoriesPre‑clinical
APCEDEN®APAC BiotechApproved
Solid Tumor ProfilingDiatech PharmacogeneticsCommercial
BAVENCIO (avelumab)EMD SeronoApproved
FoundationOne®CDx Indication ExpansionFoundation MedicineApproved/Commercial
FoundationOne®Liquid CDx Indication ExpansionFoundation MedicineApproved/Commercial
177Lu‑BetaBart (RV‑01)AtomVie Global RadiopharmaPhase 1/2a
BeiGene Oncology PortfolioEVA PharmaPhase 2/3
Bevacizumab BiosimilarBio Usawa BiotechnologyPreclinical